These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[ ]
|
Preliminary Proxy Statement
|
|
[ ]
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
[x]
|
Definitive Proxy Statement |
|
[ ]
|
Definitive Additional Materials
|
|
[ ]
|
Soliciting Material Pursuant to SS.240.14a-11(c) or SS.240.14a-12
|
|
CLEARFIELD, INC.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
|
[x]
|
No fee required. | |
|
[ ]
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |
| 1) | Title of each class of securities to which transaction applies: | |
| 2) | Aggregate number of securities to which transaction applies: | |
| 3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |
| 4) | Proposed maximum aggregate value of transaction: | |
| 5) | Total fee paid: | |
|
[ ]
|
Fee paid previously with preliminary materials | |
|
[ ]
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or Schedule and the date of its filing. | |
| 1) | Amount previously paid: | |
| 2) | Form, Schedule or Registration Statement No.: | |
| 3) | Filing Party: | |
| 4) | Date Filed: | |
|
1.
|
Elect six (6) directors to serve until the next Annual Meeting of the Shareholders or until their respective successors have been elected and qualified;
|
|
2.
|
Ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for Clearfield, Inc. for the fiscal year ending September 30, 2013.
|
|
By Order of the Board of Directors
Ronald G. Roth
Chairman of the Board of Directors
|
|
WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON,
PLEASE VOTE YOUR SHARES IN ONE OF THE WAYS
DESCRIBED IN THE PROXY STATEMENT AS PROMPTLY AS POSSIBLE.
|
|
Page
|
||
|
PROXY STATEMENT
|
1
|
|
|
Solicitation of Proxies
|
1
|
|
|
Cost and Method of Solicitation
|
1
|
|
|
Voting
|
1
|
|
|
Differences Between Shareholder of Record and Beneficial Owners
|
1
|
|
|
Quorum and Voting Requirements
|
2
|
|
|
Casting Your Vote as a Record Holder
|
2
|
|
|
Casting Your Vote as a Street Name Holder
|
2
|
|
|
Revoking a Proxy
|
3
|
|
|
Annual Meeting and Special Meetings; Bylaw Amendments
|
3
|
|
|
OWNERSHIP OF VOTING SECURITIES BY PRINCIPAL HOLDERS AND MANAGEMENT
|
4
|
|
|
PROPOSAL 1: ELECTION OF DIRECTORS
|
5
|
|
|
Information Regarding Nominees
|
5
|
|
|
Voting Required
|
6
|
|
|
CORPORATE GOVERNANCE
|
7
|
|
|
Board Independence
|
7
|
|
|
Committees of the Board of Directors and Committee Independence
|
7
|
|
|
Board Leadership Structure
|
8
|
|
|
Board’s Role in Risk Oversight
|
8
|
|
|
Director Nominations
|
9
|
|
|
Board Attendance at Board, Committee and Annual Shareholder Meetings
|
10
|
|
|
Communications with Directors
|
10
|
|
|
Code of Ethics
|
11
|
|
|
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
|
11
|
|
|
EXECUTIVE OFFICERS
|
12
|
|
|
EXECUTIVE COMPENSATION
|
12
|
|
|
Explanation of Compensation
|
12
|
|
|
Employment Arrangements with Named Executive Officers and Post-Employment Compensation
|
15
|
|
|
Summary Compensation Table
|
18
|
|
|
Grants of Plan-Based Awards in Fiscal year 2012
|
19
|
|
|
Outstanding Equity Awards at Fiscal Year-End
|
20
|
|
|
2012 Options Exercised and Stock Vested
|
21
|
|
|
DIRECTOR COMPENSATION
|
22
|
|
|
PROPOSAL 2: APPOINTMENT OF INDEPENDENT AUDITORS
|
23
|
|
|
RELATIONSHIP WITH INDEPENDENT ACCOUNTANTS
|
23
|
|
|
Accountant Fees and Services
|
23
|
|
|
Audit Committee Pre-Approval Procedures
|
23
|
|
|
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
|
24
|
|
|
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
|
25
|
|
|
SHAREHOLDER PROPOSALS AND SHAREHOLDER NOMINEES FOR 2014 ANNUAL MEETING
|
25
|
|
|
OTHER BUSINESS
|
25
|
|
|
·
|
Sending a written statement to that effect to the Secretary of Clearfield, Inc.;
|
|
·
|
Submitting a properly signed proxy card with a later date;
|
|
·
|
If you voted by telephone or through the Internet, by voting again either by telephone or through the Internet prior to the close of the voting facility; or
|
|
·
|
Voting in person at the Annual Meeting.
|
|
Name and Address of Beneficial Owner
|
Number of Shares
Beneficially Owned (1)
|
Percent of Outstanding
|
||||||
|
Ronald G. Roth (2)(3)
|
1,238,365 | 9.6% | ||||||
|
Cheryl P. Beranek (2)(4)
|
553,057 | 4.2% | ||||||
|
Charles N. Hayssen (2)
|
69,688 | * | ||||||
|
Donald R. Hayward (2)
|
27,100 | * | ||||||
|
John G. Reddan (2)
|
39,900 | * | ||||||
|
Stephen L. Zuckerman, M.D. (2)
|
32,900 | * | ||||||
|
John P. Hill (4)
|
287,852 | 2.2% | ||||||
|
Daniel R. Herzog (4)
|
70,982 | * | ||||||
|
All current executive officers and directors
as a group (8 persons)
|
2,319,844 | 17.3% | ||||||
|
*
|
Less than one percent
|
|
(1)
|
Includes shares which could be purchased within 60 days of December 27, 2012 upon the exercise of the following stock options: Mr. Roth, 2,400 shares; Ms. Beranek, 267,000 shares; Mr. Hayssen, 13,400 shares; Mr. Hayward, 13,400 shares; Mr. Reddan, 18,400 shares; Dr. Zuckerman, 4,900 shares; Mr. Hill, 181,000 shares; Mr. Herzog, 35,500 shares; and all current directors and executive officers as a group, 538,500 shares.
|
|
(2)
|
Currently serves as our director and nominated for election as a director at the Annual Meeting.
|
|
(3)
|
Includes 176,760 shares owned by Mr. Roth’s spouse.
|
|
(4)
|
Named Executive Officer.
|
|
·
|
Background, including demonstrated high personal and professional ethics and integrity;
|
|
·
|
The ability to exercise good business judgment and enhance the Board’s ability to manage and direct the affairs and business of Clearfield;
|
|
·
|
Commitment, including the willingness to devote adequate time to the work of the Board and its committees;
|
|
·
|
The ability to represent the interests of all shareholders and not a particular interest group;
|
|
·
|
The skills needed by the Board, within the context of the existing composition of the Board, including knowledge of our industry and business or experience in business, finance, law, education, research or government;
|
|
·
|
The candidate’ s qualification as “independent” under Nasdaq or other standards and qualification to serve on Board committees; and
|
|
·
|
Diversity, in terms of knowledge, experience, skills, expertise, and other demographics which contribute to the Board’s diversity.
|
|
·
|
Product inquiries, complaints or suggestions
|
|
·
|
New product suggestions
|
|
·
|
Resumes and other forms of job inquiries
|
|
·
|
Surveys
|
|
·
|
Business solicitations or advertisements
|
|
·
|
Cheryl P. Beranek, our Chief Executive Officer
|
|
·
|
Daniel R. Herzog, our Chief Financial Officer
|
|
·
|
John P. Hill, our Chief Operating Officer
|
|
2012 Cash Bonus Plan
|
||||||||
|
Name of Executive
|
% of Salary
For FY 2012
Target ICO
|
% of Salary
For FY 2012
Maximum ICO
|
||||||
|
Cheryl P. Beranek
|
60% | 150% | ||||||
|
John P. Hill
|
60% | 150% | ||||||
|
Daniel R. Herzog
|
20% | 50% | ||||||
|
·
|
In two lump sum payments, the executive’s earned but unpaid base salary and accrued but unpaid vacation through the date of termination and any prorated annual bonus required to be paid for the fiscal year that ends on or before the date of termination to the extent not previously paid and an amount equal to two times the sum of the executive’s annual base salary in effect of the date of termination plus average bonus over the prior three years;
|
|
·
|
The executive’s prorated annual bonus for the year in which the termination occurs, payable at the time bonuses are paid to the other senior executives;
|
|
·
|
We will pay premiums for the executive’s continuing coverage until the earlier of one year from the date of termination or the date on which the executive is no longer eligible for such coverage;
|
|
·
|
Any unvested stock options shall become vested in full; and
|
|
·
|
We will timely pay or provide any vested benefits or other amounts or benefits required to be paid or provided that the executive is eligible to receive on the date of termination under any plan, contract or agreement.
|
|
Name and Position
|
Year
|
Salary
($)
|
Bonus
($)(1)
|
Stock
Awards
($)(2)
|
Option
Awards
($) (2)
|
Non-
Equity
Incentive
Plan
Compen-
sation
($) (3)
|
All
Other
Compen-
sation
($) (4)
|
Total ($)
|
||||||||||||||||||||||
|
Cheryl P. Beranek
|
2012
|
$ | $263,726 | — | $ | 403,155 | — | $ | 200,000 | $ | 11,564 | $ | 878,445 | |||||||||||||||||
|
President and Chief
Executive Officer
|
2011
|
$ | $268,029 | — | — | $ | 113,187 | $ | 388,125 | $ | 12,058 | $ | 781,399 | |||||||||||||||||
|
Daniel R. Herzog
|
2012
|
$ | $149,615 | — | $ | 142,290 | — | $ | 40,000 | $ | 6,697 | $ | 338,602 | |||||||||||||||||
|
Chief Financial Officer
|
2011
|
$ | $129,991 | $ | 9,500 | — | $ | 75,458 | $ | 70,000 | $ | 3,875 | $ | 288,824 | ||||||||||||||||
|
John P. Hill
|
2012
|
$ | $248,346 | — | $ | 403,155 | — | $ | 185,000 | $ | 14,047 | $ | 850,548 | |||||||||||||||||
|
Chief Operating Officer
|
2011
|
$ | $214,423 | $ | 64,500 | — | $ | 113,187 | $ | 310,500 | $ | 11,405 | $ | 714,015 | ||||||||||||||||
|
(1)
|
For Mr. Herzog, represents $9,500 bonus approved by the Compensation Committee on August 25, 2011 for performance while serving as Interim Chief Financial Officer. For Mr. Hill, represents a bonus of $64,500 approved by the Compensation Committee on November 8, 2011 as a discretionary increase to the bonus Mr. Hill received under the cash bonus program for fiscal year 2011.
|
|
(2)
|
Represents the aggregate grant date fair value of restricted stock and stock option awards in the respective fiscal year, each as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation using the assumptions discussed in Note C, “Shareholders’ Equity,” in the notes to financial statements included in our Annual Report on Form 10-K for the years ended September 30, 2012 and 2011.
|
|
(3)
|
Represents bonuses paid to the named executive officers under our cash bonus program for the year noted, which are reported for the year in which the related services were performed.
|
|
(4)
|
Represents the following amounts:
|
|
Name
|
Year
|
Matching
Contributions to
401(k) Plan
|
Term Life
Insurance
Premiums (1)
|
|||||||
|
Cheryl P. Beranek
|
2012
|
$ | 9,959 | $ | 1,605 | |||||
|
2011
|
$ | 10,453 | $ | 1,605 | ||||||
|
Daniel R. Herzog
|
2012
|
$ | 6,697 | — | ||||||
|
2011
|
$ | 3,875 | — | |||||||
|
John P. Hill
|
2012
|
$ | 11,442 | $ | 2,605 | |||||
|
2011
|
$ | 8,800 | $ | 2,605 | ||||||
|
(1)
|
For Ms. Beranek this includes $1,605 paid by the Company for a term life insurance policy in fiscal year 2011 and fiscal year 2012, respectively. The policy began January 20, 2011, provides a $2 million benefit payable to Ms. Beranek’s estate upon her death, and expires in the year 2058. For Mr. Hill, this includes $2,605 paid by the Company for a term life insurance policy in fiscal year 2011 and fiscal year 2012, respectively. The policy began February 7, 2011, provides a $2 million benefit payable to Mr. Hill’s estate upon his death, and expires in the year 2061. The Company also has corresponding term insurance policies of each Ms. Beranek and Mr. Hill for $2 million each where the death benefit is payable to the Company.
|
|
Estimated Future Payouts Under
Non-Equity Incentive Plan Awards (1)
|
||||||||||||||
|
Name
|
Grant Date
|
Threshold
($)
|
Target
($)
|
Maximum
($)
|
||||||||||
|
Cheryl P. Beranek
|
11/17/2011
|
— | $ | 158,355 | $ | 395,888 | ||||||||
|
Daniel R. Herzog
|
11/17/2011
|
— | $ | 30,000 | $ | 75,000 | ||||||||
|
John P. Hill
|
11/17/2011
|
— | $ | 150,000 | $ | 375,000 | ||||||||
|
(1)
|
Represents bonuses that could have been earned by the named executive officers under our 2012 Bonus Plan. Under the matrix associated with the 2012 Bonus Plan, achievement of the performance goals at less than target level will result in a decreasing bonus until the achievement fails to meet the minimum performance goals, at which point the executive officer is entitled to no bonus such that there is no “threshold” level of achievement. See the column of the Summary Compensation Table entitled “Non-Equity Incentive Plan Compensation” for the amounts actually earned under the 2012 Bonus Plan. For explanation of the 2012 Bonus Plan, refer to the description under the heading of this proxy statement entitled “Executive Compensation – Explanation of Compensation – 2012 Compensation for Named Executive Officers – Design of and Payouts Under the 2012 Bonus Plan.”
|
|
Option Awards
|
Stock Awards
|
|||||||||||||||||||||||
|
Name
|
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
|
Option
Exercise
Price ($)
|
Option
Expiration
Date
|
Number of
shares of
stock that
have not
vested (#)
|
Market
value of
shares of
stock that
have not
vested
($)(1)
|
||||||||||||||||||
|
Cheryl P. Beranek (2)
|
30,000 | — | $ | 1.09 |
11/9/2013
|
|||||||||||||||||||
|
Cheryl P. Beranek (3)
|
200,000 | — | $ | 1.03 |
10/30/2018
|
|||||||||||||||||||
|
Cheryl P. Beranek (4)
|
25,000 | — | $ | 3.30 |
11/20/2016
|
|||||||||||||||||||
|
Cheryl P. Beranek (5)
|
12,000 | 18,000 | $ | 6.36 |
8/25/2016
|
|||||||||||||||||||
|
Cheryl P. Beranek (6)
|
— | — | — | — | 85,000 | $ | 434,350 | |||||||||||||||||
|
Daniel R. Herzog (4)
|
25,000 | — | $ | 3.30 |
11/20/2016
|
|||||||||||||||||||
|
Daniel R. Herzog (5)
|
8,000 | 12,000 | $ | 6.36 |
8/25/2016
|
|||||||||||||||||||
|
Daniel R. Herzog (7)
|
2,500 | 2,500 | $ | 2.58 |
8/19/2020
|
|||||||||||||||||||
|
Daniel R. Herzog (6)
|
— | — | — | — | 30,000 | $ | 153,300 | |||||||||||||||||
|
John P. Hill (2)
|
42,000 | — | $ | 1.09 |
11/9/2013
|
|||||||||||||||||||
|
John P. Hill (3)
|
102,000 | — | $ | 1.03 |
10/30/2018
|
|||||||||||||||||||
|
John P. Hill (4)
|
25,000 | — | $ | 3.30 |
11/20/2016
|
|||||||||||||||||||
|
John P. Hill (5)
|
12,000 | 18,000 | $ | 6.36 |
8/25/2016
|
|||||||||||||||||||
|
John P. Hill (6)
|
— | — | — | — | 85,000 | $ | 434,350 | |||||||||||||||||
|
(1)
|
Value based on a share price of $5.11, which was the closing sales price of our common stock on The Nasdaq Stock Market on September 28, 2012, the last trading day closest to our September 30, 2012 fiscal year end.
|
|
(2)
|
Options vest in annual installments of 20% for five years beginning on November 9, 2008 with a six year term.
|
|
(3)
|
Options vest in annual installments of 33% for three years beginning on October 30, 2009 with a ten year term.
|
|
(4)
|
Options vest in annual installments of 33.3% per year for three years beginning on November 20, 2009 with a seven year term.
|
|
(5)
|
Options vest in annual installments of 20% for five years beginning August 25, 2011 with a five year term.
|
|
(6)
|
Restricted stock vests in annual installments of 33.3% per year for three years beginning August 23, 2013.
|
|
(7)
|
Options vest in annual installments of 25% for four years beginning on August 19, 2011 with a ten year term.
|
|
Option Awards
|
||||||||
|
Name
|
Number of Shares
Acquired on Exercise (#)
|
Value Realized
on Exercise ($) (1)
|
||||||
|
Cheryl P. Beranek
|
80,000 | $234,400 | ||||||
|
Daniel R. Herzog
|
— | — | ||||||
|
John P. Hill
|
— | — | ||||||
|
(1)
|
Represents the difference between the exercise price and the fair market value of our common stock on the respective dates of exercise.
|
|
Name
|
Fees Earned or
Paid in Cash
($) (1)
|
Option Awards
($) (2)
|
Total
($)
|
|||||||||
|
Ronald G. Roth
|
$ | 10,000 | $ | 8,896 | $ | 18,896 | ||||||
|
Charles N. Hayssen
|
$ | 12,500 | $ | 8,896 | $ | 21,396 | ||||||
|
Donald R. Hayward
|
$ | 10,000 | $ | 8,896 | $ | 18,896 | ||||||
|
John G. Reddan
|
$ | 10,000 | $ | 8,896 | $ | 18,896 | ||||||
|
Stephen L. Zuckerman, M.D.
|
$ | 10,000 | $ | 8,896 | $ | 18,896 | ||||||
|
(1)
|
Represents cash retainer for fiscal year 2012 as described above.
|
|
(2)
|
Represents the aggregate grant date fair value of stock option awards in the fiscal year, each as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model using the assumptions discussed in Note C, “Shareholders’ Equity,” in the notes to financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2012.
|
|
|
The aggregate number of stock options outstanding at September 30, 2012 held by directors was: Mr. Roth, 4,900 shares; Mr. Hayssen, 13,400 shares; Mr. Hayward, 13,400 shares; Mr. Reddan, 18,400 shares; Dr. Zuckerman, 4,900 shares; and Ms. Beranek, 285,000 shares.
|
|
·
|
employment of executive officers and director compensation to be reported in our proxy statement;
|
|
·
|
ordinary course business travel and expenses, advances and reimbursements;
|
|
·
|
payments made under our articles of incorporation, bylaws, insurance policies or other agreements relating to indemnification
|
|
·
|
any transaction with another company where the related party is an employee, director or beneficial owner of that other company, if the aggregate amount involved does not exceed $50,000;
|
|
·
|
transactions in which our shareholders receive proportional benefits; and
|
|
·
|
regulated transactions at rates or charges fixed in conformity with law or governmental authority and transactions involving certain banking related services.
|
|
·
|
whether the terms are fair to us;
|
|
·
|
whether the terms of the related party transaction are no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances;
|
|
·
|
whether the related party transaction is material to us;
|
|
·
|
the role the related party has played in arranging the transaction;
|
|
·
|
the structure of the related party transaction;
|
|
·
|
the interests of all related parties in the transaction;
|
|
·
|
the extent of the related party’s interest in the transaction; and
|
|
·
|
whether the transaction would require a waiver of our Code of Ethics and Business Conduct.
|
|
By Order of the Board of Directors
Ronald G. Roth
Chairman of the Board of Director
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|